Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kushvinder Kumar

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
ACS Applied Bio Materials|March 23, 2026
Tuning Th1 Immunity through a TLR7/8 Agonist HYBRID2-Formalin-Killed <i>Leishmania donovani</i> Antigen Immunomodulatory System in Visceral LeishmaniasisSandeep Kaur, Shivani Thakur, Kushvinder Kumar, et al.
Immunology|April 13, 2026
Dual TLR7/8 Activation by Dihydroxyimidazoquinoline Adjuvant Orchestrates NF-κβ-iNOS-Driven Th1 Immunity and Durable Protection Against Leishmania donovaniShivani Thakur, Sandeep Kaur, Kushvinder Kumar, et al.
International Journal of Biological Macromolecules|February 15, 2026
Protective efficacy of heat-killed Leishmnaia donovani vaccine adjuvanted with Toll Like Receptor 7/8 agonist in BALB/c miceShivani Thakur, Sandeep Kaur, Deepender Kaushik, et al.
Drug Development Research|February 16, 2026
Novel Imidazoquinoline Based TLR7 Agonist Induces Antileishmanial Efficacy-An In Vitro StudyShivani Thakur, Kushvinder Kumar, Sandeep Kaur, et al.
Infection and Immunity|October 20, 2025
Dual immunomodulatory and antileishmanial potential of TLR7/8 agonists against <i>Leishmania donovani</i>Shivani Thakur, Deepender Kaushik, Kushvinder Kumar, et al.
Bioorganic Chemistry|April 30, 2026
Pyrazolo[1,5-c]quinazoline-based heterocycles exhibit potent antileishmanial activity: Mechanistic insights and toxicity profileSandeep Kaur, Kushvinder Kumar, Shivani Thakur, et al.
ACS Medicinal Chemistry Letters|October 16, 2024
Modulation of the Adjuvant Potential of Imidazoquinoline-Based TLR7/8 Agonists via Alum AdsorptionKushvinder Kumar, Yoshikazu Honda-Okubo, Isaac G Sakala, et al.
Chemmedchem|April 21, 2026
Design and Synthesis of New Pyrazolo[1,5-c]quinazolin-5-amines as Potential TLR7/8 ModulatorsKushvinder Kumar, Yoshikazu Honda-Okubo, Pradeep K Das, et al.
ACS Pharmacology & Translational Science|July 18, 2024
Design and Synthesis of Polyphenolic Imidazo[4,5-<i>c</i>]quinoline Derivatives to Modulate Toll Like Receptor-7 Agonistic Activity and AdjuvanticityKushvinder Kumar, Binita Sihag, Madhuri T Patil, et al.
Bioorganic & Medicinal Chemistry Letters|October 22, 2023
Imidazo[2,1-b]thiazole based indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor: Structure based design, synthesis, bio-evaluation and docking studiesRahul Singh, Ravinder Kumar, Ashalata Roy, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
ACS Applied Bio Materials|March 23, 2026
Tuning Th1 Immunity through a TLR7/8 Agonist HYBRID2-Formalin-Killed <i>Leishmania donovani</i> Antigen Immunomodulatory System in Visceral LeishmaniasisSandeep Kaur, Shivani Thakur, Kushvinder Kumar, et al.
Immunology|April 13, 2026
Dual TLR7/8 Activation by Dihydroxyimidazoquinoline Adjuvant Orchestrates NF-κβ-iNOS-Driven Th1 Immunity and Durable Protection Against Leishmania donovaniShivani Thakur, Sandeep Kaur, Kushvinder Kumar, et al.
International Journal of Biological Macromolecules|February 15, 2026
Protective efficacy of heat-killed Leishmnaia donovani vaccine adjuvanted with Toll Like Receptor 7/8 agonist in BALB/c miceShivani Thakur, Sandeep Kaur, Deepender Kaushik, et al.
Drug Development Research|February 16, 2026
Novel Imidazoquinoline Based TLR7 Agonist Induces Antileishmanial Efficacy-An In Vitro StudyShivani Thakur, Kushvinder Kumar, Sandeep Kaur, et al.
Infection and Immunity|October 20, 2025
Dual immunomodulatory and antileishmanial potential of TLR7/8 agonists against <i>Leishmania donovani</i>Shivani Thakur, Deepender Kaushik, Kushvinder Kumar, et al.
Bioorganic Chemistry|April 30, 2026
Pyrazolo[1,5-c]quinazoline-based heterocycles exhibit potent antileishmanial activity: Mechanistic insights and toxicity profileSandeep Kaur, Kushvinder Kumar, Shivani Thakur, et al.
ACS Medicinal Chemistry Letters|October 16, 2024
Modulation of the Adjuvant Potential of Imidazoquinoline-Based TLR7/8 Agonists via Alum AdsorptionKushvinder Kumar, Yoshikazu Honda-Okubo, Isaac G Sakala, et al.
Chemmedchem|April 21, 2026
Design and Synthesis of New Pyrazolo[1,5-c]quinazolin-5-amines as Potential TLR7/8 ModulatorsKushvinder Kumar, Yoshikazu Honda-Okubo, Pradeep K Das, et al.
ACS Pharmacology & Translational Science|July 18, 2024
Design and Synthesis of Polyphenolic Imidazo[4,5-<i>c</i>]quinoline Derivatives to Modulate Toll Like Receptor-7 Agonistic Activity and AdjuvanticityKushvinder Kumar, Binita Sihag, Madhuri T Patil, et al.
Bioorganic & Medicinal Chemistry Letters|October 22, 2023
Imidazo[2,1-b]thiazole based indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor: Structure based design, synthesis, bio-evaluation and docking studiesRahul Singh, Ravinder Kumar, Ashalata Roy, et al.
Pageof 2